ALXN 2420
Alternative Names: ALXN-2420; AZP-3813Latest Information Update: 27 Nov 2025
At a glance
- Originator PeptiDream
- Developer Amolyt Pharma
- Class Bicyclic peptides; Macrocyclic compounds; Peptides
- Mechanism of Action Somatotropin receptor antagonists
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Acromegaly
Most Recent Events
- 28 Oct 2025 Phase-II clinical trials in Acromegaly (Combination therapy) in USA, Argentina, Italy, Lithuania, Romania (SC) (NCT07037420)
- 24 Sep 2025 Alexion Pharmaceuticals plans a phase II ASTERIA trial for Acromegaly (Combination therapy, In adults, In the elderly) in Argentina, Brazil, China, Denmark, Hungary, Italy, Lithuania, the Netherlands, Poland, Romania, United States (SC) (NCT07037420)
- 15 Jul 2024 Amolyt Pharma has been acquired by AstraZeneca